TwinBeech Capital’s ALX Oncology ALXO Stock Holding History

TwinBeech Capital’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,500	Closed	-$462K	–	484
2021 Q4	$462K	Buy	+21,500	New	+$927K	0.03%	431

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TwinBeech Capital's ALXO Position: Q1 2022 in Review

TwinBeech Capital sold out of ALX Oncology (ALXO) in Q1 2022, closing a stake of 21,500 shares — an estimated $462K sold.

TwinBeech Capital first reported a position in ALXO in Q4 2021 and held it in 1 quarter. The position peaked at $462K in Q4 2021. 96 funds tracked by Wall St. Rank hold ALXO as of Q1 2022.

TwinBeech Capital reported no remaining ALX Oncology position as of Q1 2022 after selling out during the quarter.
TwinBeech Capital sold 21,500 ALX Oncology shares in Q1 2022, an estimated $462K.
TwinBeech Capital first reported a position in ALX Oncology in Q4 2021 and held it in 1 quarter.
TwinBeech Capital's ALX Oncology position peaked at $462K in Q4 2021.
96 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2022.

Based on TwinBeech Capital's 13F filing for Q1 2022, filed 16 May 2022.